Home › Funds › Exome Asset Management LLC › CBIO

Exome Asset Management LLC position in CBIO

CRESCENT BIOPHARMA INC. · Health Care

Exome Asset Management LLC reported holding 127,769 shares of CBIO (CRESCENT BIOPHARMA INC.) in its Q2 2026 13F filing — a position valued at US$2.3M, representing 1.42% of its reported portfolio and ranking #26 among its reported holdings. Exome Asset Management LLC has disclosed CBIO holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)127.77K sh
Reported value held$2.30M
Portfolio Weight1.42%
First reportedQ1 2026
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Exome Asset Management LLC's CBIO position evolved

Exome Asset Management LLC first disclosed a stake in CBIO in Q1 2026 at 153,191 shares (US$2.8M). Across 2 filings, Exome Asset Management LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 127,769 shares valued at US$2.3M — a reduction of -25,422 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q1 2026 153.19K $2.81M New
Q2 2026 127.77K $2.30M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CBIO and 13F data

CBIO (CRESCENT BIOPHARMA INC.) is a Health Care company. 71 other funds we track also report a position in CBIO — the largest reported positions include BVF INC/IL (US$49.5M), Fairmount Funds Management LLC (US$49.5M), Venrock Adviser, LLC (US$38.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CBIO

All CBIO fund holders →

FAQ

How long has Exome Asset Management LLC held CBIO?

Exome Asset Management LLC has disclosed CBIO holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Exome Asset Management LLC's current position in CBIO?

As of Q2 2026, Exome Asset Management LLC holds 127.77K shares of CBIO (CRESCENT BIOPHARMA INC.), valued at $2.30M, representing 1.42% of its reported portfolio and ranking #26.

Has Exome Asset Management LLC been buying or selling CBIO?

In the latest 13F filing (Q2 2026), Exome Asset Management LLC reduced its position in CBIO.

Which other funds hold CBIO?

Other major institutional holders of CBIO include BVF INC/IL, Fairmount Funds Management LLC, Venrock Adviser, LLC, among 71 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.